ID16885A - Stimulasi mekanisme pertahanan pejamu melawan tumor. - Google Patents

Stimulasi mekanisme pertahanan pejamu melawan tumor.

Info

Publication number
ID16885A
ID16885A IDP971536A ID971536A ID16885A ID 16885 A ID16885 A ID 16885A ID P971536 A IDP971536 A ID P971536A ID 971536 A ID971536 A ID 971536A ID 16885 A ID16885 A ID 16885A
Authority
ID
Indonesia
Prior art keywords
stimulation
defense mechanism
against tumors
guide against
guide
Prior art date
Application number
IDP971536A
Other languages
English (en)
Indonesian (id)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of ID16885A publication Critical patent/ID16885A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
IDP971536A 1996-05-09 1997-05-09 Stimulasi mekanisme pertahanan pejamu melawan tumor. ID16885A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms

Publications (1)

Publication Number Publication Date
ID16885A true ID16885A (id) 1997-11-20

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
IDP971536A ID16885A (id) 1996-05-09 1997-05-09 Stimulasi mekanisme pertahanan pejamu melawan tumor.
IDP971537A ID16886A (id) 1996-05-09 1997-05-09 Stimulasi mekanisme pertahanan pejamu melawan penolakan-penolakan yang disebabkan kuman virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDP971537A ID16886A (id) 1996-05-09 1997-05-09 Stimulasi mekanisme pertahanan pejamu melawan penolakan-penolakan yang disebabkan kuman virus

Country Status (17)

Country Link
EP (2) EP0956040B1 (enExample)
JP (2) JP3806446B2 (enExample)
KR (2) KR100399499B1 (enExample)
CN (1) CN1154508C (enExample)
AR (2) AR007058A1 (enExample)
AT (2) ATE316793T1 (enExample)
AU (3) AUPN976596A0 (enExample)
BR (2) BR9709223A (enExample)
CA (2) CA2253902A1 (enExample)
DE (2) DE69735204T2 (enExample)
ES (2) ES2260790T3 (enExample)
ID (2) ID16885A (enExample)
IL (2) IL126970A0 (enExample)
NZ (2) NZ332690A (enExample)
TW (1) TW528599B (enExample)
WO (2) WO1997041883A1 (enExample)
ZA (1) ZA973988B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501236A (enExample) * 1980-08-22 1982-07-15
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
AU9139091A (en) * 1990-12-14 1992-07-08 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
BR9709068A (pt) * 1996-05-09 2000-01-11 Pharma Pacific Pty Ltd Processo de tratamento.

Also Published As

Publication number Publication date
WO1997041886A1 (en) 1997-11-13
EP0898478A4 (en) 1999-05-26
JP2000504027A (ja) 2000-04-04
NZ332688A (en) 2000-07-28
JP3806446B2 (ja) 2006-08-09
DE69735204D1 (de) 2006-04-13
IL126970A0 (en) 1999-09-22
AU724190B2 (en) 2000-09-14
CA2253908A1 (en) 1997-11-13
DE69735201D1 (de) 2006-04-13
BR9709066A (pt) 2000-01-04
AU729514B2 (en) 2001-02-01
AR007058A1 (es) 1999-10-13
JP3806444B2 (ja) 2006-08-09
AR007059A1 (es) 1999-10-13
ZA973988B (en) 1998-11-09
EP0956040B1 (en) 2006-02-01
ES2260794T3 (es) 2006-11-01
KR20000010882A (ko) 2000-02-25
KR20000010880A (ko) 2000-02-25
KR100399501B1 (ko) 2003-12-18
TW528599B (en) 2003-04-21
ID16886A (id) 1997-11-20
CN1154508C (zh) 2004-06-23
AU2399297A (en) 1997-11-26
KR100399499B1 (ko) 2003-12-18
WO1997041883A1 (en) 1997-11-13
JP2000504026A (ja) 2000-04-04
AUPN976596A0 (en) 1996-05-30
IL126972A0 (en) 1999-09-22
ES2260790T3 (es) 2006-11-01
CN1218409A (zh) 1999-06-02
CA2253902A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
EP0898478A1 (en) 1999-03-03
ATE316793T1 (de) 2006-02-15
EP0898478B1 (en) 2006-02-01
EP0956040A1 (en) 1999-11-17
NZ332690A (en) 2000-07-28
DE69735201T2 (de) 2006-09-21
DE69735204T2 (de) 2006-09-21
EP0956040A4 (enExample) 1999-11-17
AU2710997A (en) 1997-11-26
BR9709223A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
NO941142D0 (no) Tumor-nekrosefaktormuteiner
DE69414482D1 (de) Tumorgewebe - Charakterisierungs-Instrument
IS4434A (is) Efnasamband til lækninga á krabbameini
DE69631736D1 (de) Stereotaktische Radiochirurgie
NL1003300A1 (nl) Implanteerbare therapeutische inrichting.
NO985331D0 (no) Ballong-kateter for fotodynamisk terapi
ID24275A (id) Terapi kombinasi
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
DE69725596D1 (de) Elektromagnetische herz-biostimulation
IT237914Y1 (it) Guida magnetica migliorata
FI925849A7 (fi) Tiazolidinfoereningar, deras framstaellning och terapeutiska anvaendningar
NO972228D0 (no) Nytt tumorsuppresor-gen, HIC-1
FI896166A0 (fi) Foerfarande foer definiering av statorfloedets estimat i en elektrisk maskin.
DK0972024T4 (da) Tumorsuppressor designeret TS10Q23.3
NO862353D0 (no) Human tumornekrosefaktor.
DE69214558D1 (de) Krebstherapiesystem
FI932492L (fi) Angiotensin ii motverkande imidazolderivat, deras framstaellning och deras terapeutiska anvaendning
FI960658A7 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
FI931079L (fi) Mikrobmotverkande karbapenemderivat, deras framstaellning och terapeutiska anvaendning
GB9509572D0 (en) Cancer therapy
FI920663L (fi) Polyhydroxicyklopentanderivat, deras framstaellning och terapeutiska anvaendning
FI961723A0 (fi) Uusi eturauhas/paksunsuolikasvaimen suppressorigeeni
IT1285594B1 (it) Dispositivo collimatore per radioterapia
MX9200725A (es) Tratamiento de cancer esofagico. tratamiento de cancer esofagico.
EP0904279A4 (en) TUMOR SUPPRESSOR GEN DPC4